Paclitaxel and topotecan in combination with rituximab as effective salvage regimen in relapsed or refractory aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Canales, MA
Sanjurjo, MJ
Garcia-Vela, JA
de Paz, R
Gracia, J
Hernandez, D
Bustos, JG
Hernandez-Navarro, F
机构：
[1] Hosp Univ La Paz, Dept Hematol, Madrid, Spain
[2] Hosp Univ Getafe, Dept Hematol, Getafe, Spain
[3] Univ Autonoma Madrid, E-28049 Madrid, Spain
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4877
引用
收藏
页码：289B / 289B
页数：1
相关论文
共 50 条
  • [31] Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Stamatoullas, A
    Fruchart, C
    Bastit, D
    Boulet, D
    Monconduit, M
    Piguet, H
    Tilly, H
    CANCER, 1996, 77 (11) : 2302 - 2307
  • [32] Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
    Keating, Gillian M.
    DRUGS, 2016, 76 (16) : 1579 - 1586
  • [33] Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
    Ogura, Michinori
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Watanabe, Takashi
    Uchida, Toshiki
    Ohmachi, Ken
    Matsumoto, Yosuke
    Tobinai, Kensei
    CANCER SCIENCE, 2011, 102 (09) : 1687 - 1692
  • [34] Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma
    Rothe, A
    Schulz, H
    Elter, T
    Engert, A
    Reiser, M
    HAEMATOLOGICA, 2004, 89 (07) : 875 - 876
  • [35] Outcome of Hodgkin's lymphoma and aggressive non-Hodgkin lymphoma patients refractory to salvage chemotherapy
    Castagna, L.
    Bramanti, S.
    Balzarotti, M.
    Giordano, L.
    Michieli, M.
    Anastasia, A.
    Magagnoli, M.
    Sarina, B.
    Todisco, E.
    Mazza, R.
    Nozza, A.
    Ibatici, A.
    Santoro, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S249 - S249
  • [36] Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
    Belada, David
    Georgiev, Pencho
    Dakhil, Shaker
    Inhorn, Lowell F.
    Andorsky, David
    Beck, J. Thaddeus
    Quick, Donald
    Pettengell, Ruth
    Daly, Robert
    Dean, James P.
    Pavlyuk, Mariya
    Failloux, Nelly
    Huebel, Kai
    FUTURE ONCOLOGY, 2016, 12 (15) : 1759 - 1768
  • [37] Chemoimmunothery with combination of Rituximab, GMCSF and CHOP in patients with previously untreated aggressive non-Hodgkin's lymphoma.
    Venugopal, P
    Wooldridge, J
    Yunus, F
    Adler, SS
    Shammo, JM
    Enschede, SH
    O'Brien, TM
    Means, A
    Nathan, S
    Venugopal, G
    Sokolovsky, TB
    Gregory, SA
    BLOOD, 2003, 102 (11) : 302B - 302B
  • [38] FND regimen (Fludarabine, mitoxantrone and dexamethasone) is an effective combination for follicular non-Hodgkin's lymphoma.
    Dell'Olio, M
    Cascavilla, N
    Musto, P
    Bodenizza, CA
    Melillo, L
    Nobile, M
    Minervini, MM
    Carella, AM
    BLOOD, 2002, 100 (11) : 300B - 300B
  • [39] Gemcitabine as single agent in the treatment of relapsed and refractory Hodgkin's and non-Hodgkin lymphoma.
    Jajeh, A
    Hadad, L
    Zalzaleh, G
    Ruestow, P
    BLOOD, 2003, 102 (11) : 285B - 285B
  • [40] Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma—Polish Lymphoma Research Group real-life analysis
    Monika Długosz-Danecka
    Iwona Hus
    Bartosz Puła
    Artur Jurczyszyn
    Tomasz Chojnacki
    Beata Blajer-Olszewska
    Joanna Drozd-Sokołowska
    Małgorzata Raźny
    Joanna Romejko-Jarosińska
    Michał Taszner
    Wojciech Jurczak
    Pharmacological Reports, 2019, 71 : 473 - 477
12345